The Full Map of Peptide Receptors That Could Treat Diabetes — Including the Multi-Target Approach Behind Tirzepatide
A 2016 review cataloged all the peptide receptors on insulin-producing cells that could be targeted for diabetes, presciently highlighting the dual and triple agonist strategy that would later produce tirzepatide and retatrutide.
Quick Facts
What This Study Found
This review maps out the landscape of peptide receptors on pancreatic beta cells that can be targeted for diabetes treatment. Beyond the well-known GLP-1 receptor, it covers GIP, glucagon, somatostatin, pancreatic polypeptide, CCK, PYY, oxyntomodulin, and ghrelin receptors — all G-protein coupled receptors (GPCRs) that regulate insulin secretion and metabolism.
Critically, the review highlights the emerging strategy of dual and triple agonist peptides that activate two or more of these receptors simultaneously. It also covers fatty acid GPCRs (GPR40, GPR41, GPR43, GPR84, GPR119, GPR120) that regulate peptide hormone secretion and represent additional drug targets.
Key Numbers
9+ peptide GPCRs on beta cells · 6 fatty acid GPCRs · Dual and triple agonist approaches · GLP-1, GIP, glucagon, somatostatin, PP, CCK, PYY, OXM, ghrelin receptors
How They Did This
Narrative review of the current state of peptide GPCR drug development for type 2 diabetes, covering receptor biology, existing agonists, and emerging multi-agonist peptide strategies. Includes both preclinical and clinical evidence.
Why This Research Matters
This 2016 review was remarkably prescient — the dual and triple agonist approach it described would go on to produce tirzepatide (GLP-1/GIP dual agonist, approved 2022) and retatrutide (GLP-1/GIP/glucagon triple agonist, in Phase 3 trials). Understanding the full map of peptide GPCRs on beta cells explains why multi-targeting approaches are more effective than single-receptor drugs for metabolic disease.
The Bigger Picture
This review captured a pivotal moment in metabolic drug development — the shift from single-target GLP-1 drugs to multi-receptor peptide agonists. The landscape it described has since exploded: tirzepatide became a blockbuster dual agonist, and triple agonists like retatrutide and survodutide are in advanced trials. The fatty acid GPCR targets it discussed also remain active research areas.
What This Study Doesn't Tell Us
Published in 2016, so it predates the clinical validation of many concepts it describes (e.g., tirzepatide's Phase 3 success). As a narrative review, it summarizes rather than systematically evaluates the evidence. Some receptor targets discussed remain preclinical.
Questions This Raises
- ?Is there an upper limit to how many receptors a single peptide can effectively target without unacceptable side effects?
- ?Which combination of the 9+ peptide GPCRs produces the best metabolic outcomes with the fewest adverse effects?
- ?Can fatty acid GPCR agonists complement peptide receptor agonists for enhanced metabolic control?
Trust & Context
- Key Stat:
- 9+ peptide GPCRs targetable on beta cells Beyond GLP-1, pancreatic beta cells express receptors for GIP, glucagon, somatostatin, CCK, PYY, and more — enabling the multi-agonist strategy behind today's most effective metabolic drugs.
- Evidence Grade:
- This is a narrative review summarizing the state of GPCR drug development as of 2016. It synthesizes preclinical and clinical evidence across many receptor targets but does not present original data or use systematic review methodology.
- Study Age:
- Published in 2016 — before tirzepatide's clinical success validated the dual agonist concept. While some specific trial details are outdated, the receptor biology and multi-agonist framework described remain foundational to current metabolic drug development.
- Original Title:
- Development of novel ligands for peptide GPCRs.
- Published In:
- Current opinion in pharmacology, 31, 57-62 (2016)
- Authors:
- Moran, Brian M, McKillop, Aine M, O'Harte, Finbarr Pm
- Database ID:
- RPEP-03054
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What are peptide GPCRs and why do they matter for diabetes treatment?
G-protein coupled receptors (GPCRs) are proteins on cell surfaces that respond to peptide hormones. Insulin-producing beta cells in the pancreas have many of them — for GLP-1, GIP, glucagon, and other hormones. Activating these receptors with synthetic peptide drugs can stimulate insulin release and improve blood sugar control.
What are dual and triple agonist peptides?
These are synthetic peptides designed to activate two or three receptors at once. For example, tirzepatide (Mounjaro) activates both GLP-1 and GIP receptors. Triple agonists like retatrutide add glucagon receptor activation. Hitting multiple targets appears to produce stronger metabolic benefits than targeting a single receptor.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-03054APA
Moran, Brian M; McKillop, Aine M; O'Harte, Finbarr Pm. (2016). Development of novel ligands for peptide GPCRs.. Current opinion in pharmacology, 31, 57-62. https://doi.org/10.1016/j.coph.2016.08.009
MLA
Moran, Brian M, et al. "Development of novel ligands for peptide GPCRs.." Current opinion in pharmacology, 2016. https://doi.org/10.1016/j.coph.2016.08.009
RethinkPeptides
RethinkPeptides Research Database. "Development of novel ligands for peptide GPCRs." RPEP-03054. Retrieved from https://rethinkpeptides.com/research/moran-2016-development-of-novel-ligands
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.